Sick Sigma Lubricates!

Quote






Mass terminations, of course. Including legal work-arounds that allow the company to get only positive press while engaging in mass termination of qualified professionals. The ethics are not within our consideration during this study. Promises made a decade ago have no bearing on the current business cycle. The end of this study, which is to ensure the company's survival, and also survival of a 6% dividend despite the lack of any foreseeable new drug entities, will justify the means: THE TERMINATION OF YOUR EXISTENCE in any financial sense with respect to company obligations. Bye.
 






Since its inception, Six Sigma has established itself among the management and HR ranks as the premier tool for legally reducing the workforce. Gains in process efficiency are little to none as the result of Six Sigma projects. The goal alway has been and will be to reduce the workforce for those who see people as an expense and not an asset. Unfortunately efficiency does not produce innovative drugs nor does it promote quality work among those actually doing the work. In essence, Six Sigma is get rich quick scheme used by unethical leadership teams. Since Six Sigma was brought to Lilly several Lilly leaders have retired as multi-millionaire while countless other have found their careers in ruin. The FACTS speak louder than the leadership rhetoric.
 






Agree with above posts. This is not a leadership company, nor is this an innovation company, for the following reasons to be discussed. First and foremost, is the continued survival of the company as an individual equity on the NYSE. The current price to earnings ratio (P/E) is about 7, which is symptomatic of a company faced with a large short-term earnings shortfall. Further, the dividend is about 6% of the current stock price. This raises a number of flags for a number of reasons. Most innovation companies have little or no dividend, as research can be expected to bring very large returns, far exceeding any short term gain investors might expect.
 
























I disagree with all of you. Six Sigma works and it works well. Since bringing it into Lilly, my compensation package has grown nearly 800%. That's what I call an "Answer that Matters".

$$ JL $$
 












Anonymous said:
Yes, and the pipeline is the best ever. Over sixty molecules ready for Phase III. We better not merge or it will be bad for stockholders.
Click to expand...

Six Sigma is great for reducing variation in a process. This is wonderful when you want a repeatable process. However, innovation is by definition stepping outside an existing process and creating something new. By its very nature, Six Sigma squelches that and, thus, any chance this company has of doing anything of value. Maybe they will get lucky and buy something that accidentally turns out to be a winner or maybe we will see then sub-letting portions of LTC-S out to the airport for a "park-n-ride." Either way the company is a shell of what it once was.
 






Wow! Just LOOK at that early stage pipeline so clearly disclosed in the annual report. Why, there's "Cancer" and "Depression" and "Migraine!" Surely, that will make up for multiple PhaseIII failures! Because at LILLIE: BÛLLŠHÎT THAT ŠPLÂTTÊRŠ™
 






Re: You and Your Future

There is something we can all do that is positive about our future: Take a nice "SHORT" position in Lilly stock. As it descends into the chilly depths, go ahead, buy that champagne! Hey I'll see you at the steak joint downtown.
 






Top Bottom
Back
Quote